Mural Oncology Plc Quick Ratio (MURA) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mural Oncology Plc  (NASDAQ: MURA)

Mural Oncology Plc's Quick Ratio

MURA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Mural Oncology Plc's Cash & cash equivalent, this led to improvement in Mural Oncology Plc's Quick Ratio to 5.59, Quick Ratio remained below Mural Oncology Plc average.

Within Major Pharmaceutical Preparations industry 158 other companies have achieved higher Quick Ratio than Mural Oncology Plc in third quarter 2025. While Quick Ratio total ranking has improved so far during the Q3 2025 to 504, from total ranking in the second quarter 2025 at 767.

Explain Quick Ratio?
How much Cash & cash equivalents MURA´s has?
What are MURA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MURA Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change -57.73 % 15.4 % 8.97 % -9.73 % -5.66 %
Y / Y Cash & cash equivalent Change -66.46 % -62.34 % -53.52 % -46.69 % -
Quick Ratio MRQ 5.59 2.71 4.65 5.51 7.04
MURA's Total Ranking # 504 # 767 # 468 # 437 # 366
Seq. Current Liabilities Change -62.95 % 22.74 % -11.61 % 5.14 % 1.17 %
Seq. Cash & cash equivalent Change -23.64 % -28.41 % -25.42 % -17.73 % -14.27 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 159
Healthcare Sector # 249
Overall Market # 504


Quick Ratio Statistics
High Average Low
10.9 6.76 2.71
(Mar 31 2024)   (Jun 30 2025)




Financial Statements
Mural Oncology Plc's Current Liabilities $ 11 Millions Visit MURA's Balance sheet
Mural Oncology Plc's Cash & cash equivalent $ 59 Millions Visit MURA's Balance sheet
Source of MURA's Sales Visit MURA's Sales by Geography


Cumulative Mural Oncology Plc's Quick Ratio

MURA's Quick Ratio for the trailling 12 Months

MURA Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -11.53 % 1.37 % -13.65 % 3.98 % 55.32 %
Y / Y Cash & cash equivalent TTM Growth -56.04 % -28.64 % 25.82 % 179.22 % -
Quick Ratio TTM 4.39 4.91 6.39 7.8 8.84
Total Ranking TTM # 3087 # 2793 # 2357 # 3146 # 2923
Seq. Current Liabilities TTM Growth -14.01 % 3.84 % 1.97 % -2.83 % -1.47 %
Seq. Cash & cash equivalent TTM Growth -23.11 % -20.18 % -16.4 % -14.33 % 24.82 %

Quick ratio ranking by company, industry and sector >> Back to MURA Financial Strength Comparisons >> Go to Compare MURA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in MURA's Current Liabilities to $10.53 millions, cumulative Quick Ratio to 4.39 below the MURA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 417 other companies have achieved higher Quick Ratio than Mural Oncology Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2793 to 3087.

Explain Quick Ratio?
How much Cash & cash equivalents MURA´s has?
What are MURA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 418
Healthcare Sector # 858
Within the Market # 3087


trailing twelve months Quick Ratio Statistics
High Average Low
8.84 6.55 4.39
(Sep 30 2024)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Alto Neuroscience Inc   15.24 $ 137.816  Millions$ 9.045  Millions
Rezolute Inc   14.91 $ 152.194  Millions$ 10.209  Millions
Nkarta Inc   14.87 $ 282.331  Millions$ 18.988  Millions
Crinetics Pharmaceuticals Inc   14.73 $ 1,092.291  Millions$ 74.155  Millions
Eupraxia Pharmaceuticals Inc   14.52 $ 80.563  Millions$ 5.550  Millions
Oric Pharmaceuticals Inc   14.23 $ 287.140  Millions$ 20.179  Millions
Avalo Therapeutics Inc   14.01 $ 111.707  Millions$ 7.972  Millions
Arrivent Biopharma inc   13.96 $ 300.266  Millions$ 21.502  Millions
Structure Therapeutics Inc   13.89 $ 799.043  Millions$ 57.527  Millions
Kairos Pharma Ltd   13.87 $ 5.575  Millions$ 0.402  Millions
Adc Therapeutics Sa  13.86 $ 234.738  Millions$ 16.937  Millions
Bicara Therapeutics Inc   13.80 $ 290.167  Millions$ 21.028  Millions
Cryoport inc   13.77 $ 423.411  Millions$ 30.749  Millions
Pliant Therapeutics Inc   13.72 $ 241.797  Millions$ 17.624  Millions
Novabridge Biosciences  13.49 $ 32.246  Millions$ 2.391  Millions
Amylyx Pharmaceuticals Inc   13.34 $ 343.990  Millions$ 25.791  Millions
Dyne Therapeutics Inc   13.23 $ 791.887  Millions$ 59.849  Millions
Rallybio Corporation  13.13 $ 59.319  Millions$ 4.519  Millions
Bridgebio Oncology Therapeutics Inc   13.11 $ 468.285  Millions$ 35.712  Millions
Pepgen Inc   12.95 $ 163.665  Millions$ 12.642  Millions
Sagimet Biosciences inc   12.92 $ 116.693  Millions$ 9.031  Millions
Newamsterdam Pharma Company N v   12.91 $ 702.946  Millions$ 54.459  Millions
Protagonist Therapeutics inc   12.82 $ 576.117  Millions$ 44.942  Millions
Context Therapeutics Inc   12.75 $ 76.938  Millions$ 6.036  Millions
Maplight Therapeutics Inc   12.24 $ 227.168  Millions$ 18.562  Millions
Ideaya Biosciences Inc   12.20 $ 786.894  Millions$ 64.509  Millions
Xenon Pharmaceuticals Inc   12.06 $ 462.268  Millions$ 38.335  Millions
Vera Therapeutics Inc   12.01 $ 497.389  Millions$ 41.407  Millions
Siga Technologies Inc  11.78 $ 171.956  Millions$ 14.602  Millions
Aardvark Therapeutics Inc   11.77 $ 126.350  Millions$ 10.736  Millions

Date modified: 2026-08-29T17:49:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.